Hanmi Pharmaceutical Co., Ltd. - 18 Mar 2025 Form 3 Insider Report for Aptose Biosciences Inc. (APTOF)

Role: 10%+ Owner
Signature: HANMI PHARMACEUTICAL CO., LTD.; By: /s/ Haegon Shin, Managing Director, Global Business Division
Issuer symbol: APTOF
Transactions as of: 18 Mar 2025
Net transactions value: $0
Form type: 3
Filing time: 20 Mar 2025, 20:54:45 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	APTO	Common Shares						508,710	18 Mar 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	APTO	Warrants to Purchase Common Shares							18 Mar 2025	Common Shares	77,972	$51.30	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
F2	Represents the exercise price per Common Share of the Issuer issuable upon the exercise of the Warrants, as adjusted following the Issuer's 30-to-1 reverse stock split.